Ensign Group (ENSG) is back in focus after reporting revenue up 18.4% year over year, yet missing analysts’ estimates by 8.4%. This combination has cooled sentiment despite its established skilled nursing footprint.

The share price has pulled back recently, with a 30 day share price return of down 9.1% and a 90 day share price return of down 19.7%. However, the 1 year total shareholder return of 19.1% and 5 year total shareholder return of 108.9% reflect a much stronger longer term picture, suggesting that momentum has cooled after the earnings miss.

If you are reassessing your healthcare exposure after Ensign Group’s update, this is a useful moment to scan for other specialised healthcare opportunities through the 34 healthcare AI stocks.

With revenue up 18.4% year over year but an 8.4% miss versus expectations and the stock trading at a discount of 28.2% to the consensus price target, you have to ask: is this a reset buying opportunity, or is the market already pricing in all the growth ahead?

Price-to-Earnings of 27.4x: Is it justified?

On a P/E of 27.4x, Ensign Group trades at a higher earnings multiple than both the US Healthcare industry average of 24.6x and its peer average of 14.3x. With the last close at $171.94, the stock price reflects a richer valuation than many investors might expect for this part of the healthcare sector.

The P/E ratio compares the current share price to the company’s earnings per share and is one of the most commonly watched markers for how much investors are paying for each dollar of profit. For a company like Ensign Group, which operates skilled nursing and post acute care facilities, a higher P/E can sometimes signal that the market is willing to pay up for consistent earnings growth and perceived quality of those earnings.

Here, the 27.4x P/E stands above both the Healthcare industry at 24.6x and the estimated fair P/E of 23.8x. Investors are therefore paying a clear premium to sector norms and to the level the SWS model suggests the market could move toward over time. That premium sits on top of a backdrop where earnings have grown 13.6% per year over the past 5 years and 17.4% over the past year, with earnings also forecast to grow, but not at what the model classifies as a significant rate.

Result: Price-to-Earnings of 27.4x (OVERVALUED)

However, investors still need to weigh risks such as regulatory or reimbursement changes in skilled nursing, as well as any reversal in recent revenue or net income growth trends.

Another View: What Does The Cash Flow Say?

While the P/E suggests Ensign Group trades at a premium, the SWS DCF model points the other way. With the stock at $171.94 and the DCF value at $164.13, it screens as overvalued on future cash flows. This raises a simple question: which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across earnings, valuation, and sentiment, are you comfortable just taking the headline view, or do you want to test it against the underlying data yourself? If you are weighing what the market might be seeing on the upside, it could be useful to dig into the company's 3 key rewards.

Looking for more investment ideas?

Once you have formed a view on Ensign Group, do not stop there. Widen your watchlist with a few focused stock ideas that match different goals.

• Target potential mispricings by scanning for companies that combine quality fundamentals with lower valuations through the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing higher yielding opportunities through the 10 dividend fortresses before the next round of payouts passes you by.
• Prioritise capital preservation by filtering for sturdier balance sheets and consistent fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.